Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesARTRYA Ltd

ARTRYA Ltd

Healthcare Health Information Services
PortfolioPortfolio WatchlistWatchlist
Company price
3.57 AUD -0.24 ( 6.30%)
Last update at 2026-09-28T06:10:00Z
VOLUME
1445482
Market Cap
650.45M

Momentum Score

…

Artrya Limited, a medical technology company, engages in the development and commercialization of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. It offers Salix, a suite of cloud-based software that uses artificial intelligence to automate the detection of coronary artery disease from coronary computed tomography angiography scans to identify and manage patients at risk of a heart attack. The company was incorporated in 2018 and is based in West Perth, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.51
Low
3.79
High
52 Week Price Range
2.18
Low
6.49
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Artrya Ltd is an Australian company developing artificial intelligence software for image-based medical diagnostics and decision support.

Long-term growth may be driven by wider AI adoption, successful clinical validation and regulatory approvals, and licensing or subscription models that could support scalable revenue, which may make the company attractive to investors seeking software-led exposure to healthcare diagnostics.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.81
Dividend Yield
-
Revenue TTM
0.03M
Revenue Per Share
-
Gross Profit TTM
-20.02M
Debt / Equity
0.00
ROE
-50.58%
Net Debt
-43.93M
ROCE
-34.00%
Diluted EPS TTM
-0.17

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -25.18M -16.38M -13.97M -11.12M -16.62M
Net income -25.18M -16.41M -14.00M -11.14M -17.16M
Selling general administrative 14.72M 0.67M 0.47M 10.88M 8.98M
Selling and marketing expenses - 0.05M 0.09M - 1.70M
Gross profit -1.23M -15.99M -13.25M - -
Reconciled depreciation 1.25M 1.19M 2.00M 0.55M 0.20M
Ebit -27.29M -16.62M -14.36M -11.45M -16.61M
Ebitda -26.04M -16.21M -13.96M -11.89M -16.41M
Depreciation and amortization 1.25M 0.41M 0.40M - 0.20M
Operating income -27.29M -16.62M -14.40M -11.46M -16.61M
Other operating expenses 27.32M 16.65M 14.40M 0.02M 16.79M
Interest expense 0.02M 0.03M 0.03M 0.02M 0.01M
Tax provision 0.00M 0.03M 0.03M 0.02M 0.54M
Interest income 2.43M 0.27M 0.46M 0.35M 0.07M
Net interest income 2.42M 0.24M 0.43M 0.35M 0.05M
Income tax expense 0.00M 0.03M 0.03M 0.02M 0.54M
Total revenue 0.03M 0.03M 0.00M 0.00M 0.00M
Total operating expenses 26.07M 0.63M 1.15M - 16.79M
Cost of revenue 1.25M 16.02M 13.25M - -
Total other income expense net 2.11M 0.24M 0.43M 0.98M 0.11M
Net income from continuing ops -25.18M -16.41M -14.00M -11.14M -17.16M
Net income applicable to common shares - -16.41M -14.00M -11.14M -17.16M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 85.35M 23.68M 19.01M 33.09M 43.87M
Intangible assets 4.63M 5.09M - 7.17M 3.67M
Other current assets 0.24M 0.42M 0.38M 0.15M -
Total liab 7.06M 2.39M 2.21M 2.53M 3.23M
Total stockholder equity 78.29M 21.29M 16.80M 30.56M 40.64M
Other current liab 4.21M 1.02M 1.05M 0.88M 1.39M
Common stock 154.39M 75.05M 56.45M 56.44M 56.40M
Capital stock 154.39M - - 56.44M 56.40M
Retained earnings -89.46M -64.28M -47.87M -33.87M -22.74M
Other liab - - - - 0.02M
Cash 44.17M 11.33M 7.28M 20.13M 15.29M
Total current liabilities 5.08M 2.07M 1.57M 1.59M 2.06M
Net debt -43.93M -10.71M -6.33M - -13.92M
Short term debt 0.25M 0.70M 0.33M 0.00M 0.22M
Short long term debt total 0.25M 0.62M 0.95M - 1.37M
Other stockholder equity - - - 7.99M 6.98M
Property plant equipment - - - 2.21M 2.32M
Total current assets 79.77M 17.13M 11.54M 23.71M 37.87M
Net tangible assets - - - 23.39M 36.97M
Short term investments 30.00M 0.15M 0.00M 0.13M 20.27M
Net receivables 5.36M 5.38M 3.87M 3.07M 1.99M
Accounts payable 0.62M 0.36M 0.20M 0.24M 0.45M
Accumulated other comprehensive income 13.36M 10.52M 8.23M - 6.98M
Non currrent assets other - - 5.73M - -
Non current assets total 5.58M 6.54M 7.47M 9.38M 6.00M
Capital lease obligations 0.25M - - 1.21M 1.37M
Long term debt total - - - 0.94M 1.15M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments -30.00M 0.01M 2.71M 20.00M -20.27M
Change to liabilities - - - -0.41M 0.52M
Total cashflows from investing activities -30.50M 0.01M 2.71M 16.27M -26.59M
Net borrowings - - - -0.27M -0.11M
Total cash from financing activities 79.00M 18.46M -0.30M -0.24M 38.53M
Change to operating activities - - - -0.17M 0.20M
Net income -25.18M -16.41M -14.00M -11.14M -17.16M
Change in cash 32.69M 4.20M -13.00M 4.85M 2.30M
Begin period cash flow 11.48M 7.13M 20.13M 15.29M 12.98M
End period cash flow 44.17M 11.33M 7.13M 20.13M 15.29M
Total cash from operating activities -15.77M -14.27M -15.41M -11.19M -9.65M
Issuance of capital stock 84.14M 20.07M 0.01M 0.02M 40.01M
Depreciation 1.25M 1.19M 2.00M 0.52M 0.20M
Other cashflows from investing activities - 0.27M 2.75M 2.22M 0.07M
Change to account receivables 0.16M -1.45M 0.62M 0.43M 0.69M
Sale purchase of stock -4.79M -1.28M 0.01M 0.02M -2.25M
Other cashflows from financing activities -0.35M -1.28M -0.31M 0.00M 0.78M
Change to netincome - - - -0.45M 5.89M
Capital expenditures 0.14M 0.26M 0.05M 0.29M 6.38M
Change in working capital 0.71M -1.30M 0.69M 0.54M 0.97M
Stock based compensation - 2.14M 0.23M - -
Other non cash items 7.45M 0.11M -4.32M - -
Free cash flow -15.91M -14.53M -15.41M -15.74M -6.38M

Peer Comparison*

Sector: Healthcare Industry: Health Information Services

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
AYA
ARTRYA Ltd		 -0.24
6.30%		 3.57 - - 23230.33 8.10 20004.93 0.33
PME
Pro Medicus Ltd		 1.15
0.71%		 162.15 64.69 89.29 65.34 37.37 63.47 81.35
CGS
Cogstate Ltd		 -0.06
1.78%		 3.31 36.00 28.17 9.16 6.93 6.33 19.23
EIQ
Echoiq Ltd		 -0.05
8.47%		 0.54 - - 5395.50 40.77 5059.22 -8.27
ALC
Alcidion Group Ltd		 -
-%		 0.10 - 1.23 2.68 1.49 2.75 18.06

Profile*

ARTRYA Ltd

Artrya Limited, a medical technology company, engages in the development and commercialization of artificial intelligence platform that detects, diagnoses, and address coronary artery disease in Australia. It offers Salix, a suite of cloud-based software that uses artificial intelligence to automate the detection of coronary artery disease from coronary computed tomography angiography scans to identify and manage patients at risk of a heart attack. The company was incorporated in 2018 and is based in West Perth, Australia.

1257 Hay Street, West Perth, WA, Australia, 6005

61 8 6478 7816

https://www.artrya.com

Name Title Year Born
Mr. John Windsor Barrington A.M., F.A.C.I.D., M.B.A. Co-founder, CEO, MD & Director NA
Mr. John Konstantopoulos B.E. Co-Founder, Exec. Director of Product & Director NA
Mr. Mark Wainwright Chief Financial Officer NA
Dr. Julien Flack Chief Technology Officer NA
Prof. Girish Dwivedi M.D. Chief Scientific Officer NA
Ms. Janice Marcon Chief People & Culture Officer NA
Dr. Jacob Agris M.D., Ph.D. Chief Medical Officer NA
Mr. Riaz Kingston Head of Bus. Devel. NA
Dr. Jacque J. Sokolov B.A., M.D. Non-Exec. Director, Chair & Pres of Artrya USA Inc 1955
Mr. Ted Schwab Co-CEO of Artrya USA Inc NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GQC
CAD 0.85
+23.19%
DHT-U
CAD 13.90
+7.01%
ACQ
CAD 22.98
+6.78%
IE
CAD 14.79
+5.95%
SGD
CAD 17.50
+5.68%
SLI
CAD 2.63
-9.00%
FLT
CAD 0.58
-6.45%
SGR-U
CAD 7.56
-6.44%
BB
CAD 11.57
-5.71%
SGR-UN
CAD 10.75
-5.70%

Equity Sectors*

  • Basic Materials

    +0.57%

  • Communication Services

    -1.04%

  • Consumer Cyclical

    +1.42%

  • Consumer Defensive

    +0.27%

  • Energy

    -0.96%

  • Financial Services

    +0.26%

  • Healthcare

    +0.72%

  • Industrials

    +0.43%

  • Real Estate

    +0.40%

  • Technology

    -0.33%

  • Utilities

    -0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…